ADSIVITI Trademark

Trademark Overview


On Monday, November 15, 2021, a trademark application was filed for ADSIVITI with the United States Patent and Trademark Office. The USPTO has given the ADSIVITI trademark a serial number of 97125468. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, October 28, 2024. This trademark is owned by Eli Lilly and Company. The ADSIVITI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
adsiviti

General Information


Serial Number97125468
Word MarkADSIVITI
Filing DateMonday, November 15, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, October 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 20, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, November 18, 2021NEW APPLICATION ENTERED
Friday, November 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 12, 2022ASSIGNED TO EXAMINER
Monday, August 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 31, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 20, 2022PUBLISHED FOR OPPOSITION
Tuesday, September 20, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 17, 2023SOU EXTENSION 1 FILED
Monday, April 17, 2023SOU EXTENSION 1 GRANTED
Wednesday, April 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 16, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 16, 2023SOU EXTENSION 2 FILED
Monday, October 16, 2023SOU EXTENSION 2 GRANTED
Wednesday, October 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, April 16, 2024SOU EXTENSION 3 FILED
Tuesday, April 16, 2024SOU EXTENSION 3 GRANTED
Wednesday, April 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 28, 2024SOU TEAS EXTENSION RECEIVED
Monday, October 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 28, 2024SOU EXTENSION 4 FILED
Monday, October 28, 2024SOU EXTENSION 4 GRANTED